Research programme: melanocortin-4 receptor agonists - Amura
Latest Information Update: 06 Jul 2010
At a glance
- Originator Amura
- Mechanism of Action Melanocortin type 4 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 07 Jun 2006 Preclinical trials in Obesity in United Kingdom (PO)